Drug Profile
Research programme: aminoglycoside antibacterials - Achaogen
Alternative Names: Expanded-spectrum aminoglycosides - Achaogen; NeoglycosidesLatest Information Update: 24 Aug 2022
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Achaogen
- Class Aminoglycosides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 24 Aug 2022 Discontinued - Preclinical for Bacterial infections in USA (Parenteral)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 26 Apr 2018 Preclinical development is ongoing in USA